Evolution of the Cannabinoid and Terpene Content during the Growth of Cannabis sativa Plants from Different Chemotypes

被引:351
作者
Aizpurua-Olaizola, Oier [1 ,2 ]
Soydaner, Umut [1 ]
Oeztuerk, Ekin [1 ]
Schibano, Daniele [1 ]
Simsir, Yilmaz [1 ]
Navarro, Patricia [2 ]
Etxebarria, Nestor [2 ]
Usobiaga, Aresatz [2 ]
机构
[1] Aifame GmbH, Tufi 450, CH-9105 Wald Schonengrund, Switzerland
[2] Univ Basque Country, UPV EHU, Dept Analyt Chem, Barrio Sarriena S-N, Leioa 48940, Spain
来源
JOURNAL OF NATURAL PRODUCTS | 2016年 / 79卷 / 02期
关键词
ALZHEIMERS-DISEASE; CHEMICAL PHENOTYPE; MARIJUANA; THC; CANNABICHROMENE; ACCUMULATION; INHERITANCE; DRONABINOL; ANOREXIA; MODULATE;
D O I
10.1021/acs.jnatprod.5b00949
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
The evolution of major cannabinoids and terpenes during the growth of Cannabis sativa plants was studied. In this work, seven different plants were selected: three each from chemotypes I and III and one from chemotype II. Fifty clones of each mother plant were grown indoors under controlled conditions. Every week, three plants from each variety were cut and dried, and the leaves and flowers were analyzed separately. Eight major cannabinoids were analyzed via HPLC-DAD, and 28 terpenes were quantified using GC-FID and verified via GC-MS. The chemotypes of the plants, as defined by the tetrahydrocannabinolic acid/cannabidiolic acid (THCA/CBDA) ratio, were clear from the beginning and stable during growth. The concentrations of the major cannabinoids and terpenes were determined, and different patterns were found among the chemotypes. In particular, the plants from chemotypes II and III needed more time to reach peak production of THCA, CBDA, and monoterpenes. Differences in the cannabigerolic acid development among the different chemotypes and between monoterpene and sesquiterpene evolution patterns were also observed. Plants of different chemotypes were clearly differentiated by their terpene content, and characteristic terpenes of each chemotype were identified.
引用
收藏
页码:324 / 331
页数:8
相关论文
共 57 条
[31]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC PROFILING OF CANNABIS PRODUCTS [J].
LEHMANN, T ;
BRENNEISEN, R .
JOURNAL OF LIQUID CHROMATOGRAPHY, 1995, 18 (04) :689-700
[32]   Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials [J].
Lynch, Mary E. ;
Campbell, Fiona .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (05) :735-744
[33]   Non-psychoactive cannabinoids modulate the descending pathway of antinociception in anaesthetized rats through several mechanisms of action [J].
Maione, Sabatino ;
Piscitelli, Fabiana ;
Gatta, Luisa ;
Vita, Daniela ;
De Petrocellis, Luciano ;
Palazzo, Enza ;
de Novellis, Vito ;
Di Marzo, Vincenzo .
BRITISH JOURNAL OF PHARMACOLOGY, 2011, 162 (03) :584-596
[34]  
Mandolino G., 2003, Journal of Industrial Hemp, V8, P51, DOI 10.1300/J237v08n02_04
[35]  
McPartland J. M., 2001, Journal of Cannabis Therapeutics, V1, P103, DOI 10.1300/J175v01n03_08
[36]   Cannabidiol: An overview of some pharmacological aspects [J].
Mechoulam, R ;
Parker, LA ;
Gallily, R .
JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (11) :11S-19S
[37]  
Morgan CJ, 2011, ADDICT BEHAV, V38, P2433
[38]   Δ9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome:: A 6-week randomized trial [J].
Müller-Vahl, KR ;
Schneider, U ;
Prevedel, H ;
Theloe, K ;
Kolbe, H ;
Daldrup, T ;
Emrich, HM .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (04) :459-465
[39]   Treatment of Tourette's syndrome with Δ9-tetrahydrocannabinol (THC):: A randomized crossover trial [J].
Müller-Vahl, KR ;
Schneider, U ;
Koblenz, A ;
Jöbges, M ;
Kolbe, H ;
Daldrup, T ;
Emrich, HM .
PHARMACOPSYCHIATRY, 2002, 35 (02) :57-61
[40]   Plant volatile terpenoid metabolism: Biosynthetic genes, transcriptional regulation and subcellular compartmentation [J].
Nagegowda, Dinesh A. .
FEBS LETTERS, 2010, 584 (14) :2965-2973